Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.35 |
| ▸ | LTC4S | Q16873 | 4/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560977 | 0.76 | KMO (0.45) | KMOKMT2ASTING1LTC4S | |
| SCHEMBL9259401 | 0.71 | — | — | |
| SCHEMBL8307343 | 0.71 | — | — | |
| SCHEMBL5560640 | 0.69 | KMO (0.57) | KMOKMT2ASTING1LTC4S | |
| Hydrochloric Acid SCHEMBL11471359 | 0.69 | GSK3B (0.57) | GSK3B | |
| SCHEMBL5561860 | 0.68 | GSK3B (0.40) | GSK3B | |
| SCHEMBL5562600 | 0.68 | DAO (0.55) | KMOGSK3BKMT2ASTING1LTC4S | |
| SCHEMBL5561431 | 0.68 | KMO (0.47) | KMOKMT2ASTING1LTC4S | |
| SCHEMBL5560911 | 0.68 | KMO (0.51) | KMOKMT2ALTC4S | |
| SCHEMBL16615456 | 0.67 | LCK (0.52) | KMOSTING1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565451-B1 | HALOTHIENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-05-09 | — | — | EP | disclosed |
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2006-06-01 | — | — | US | disclosed |
| EP-1565451-A1 | HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048361-A1 | HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2004-06-10 | — | — | WO | disclosed |
| EP-1424333-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116329-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | KMO, HAO1, DAO | KMO 1/4885GSK3B 3543/4885KMT2A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.